Post-ASH 2021 iwNHL

27–28 January 2022 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in Non-Hodgkin Lymphoma (NHL) from ASH 2021

The Post-ASH 2021 iwNHL Virtual Workshop was held on 27-28 January 2022. The program covered key topics in the area of non-Hodgkin lymphoma. Both days featured a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.

NHL; Follicular Lymphoma Novel Therapies CLL & SLL T-Cell Engagement & Therapies

Session 1: NHL; Follicular Lymphoma

Anand Jeyasekharan

Ex-vivo platform for choice of drug combinations in R/R lymphoma

Anand Jeyasekharan National University of Singapore, Singapore, Singapore

FLIPI24: EFS & OS in patients with FL treated with immunochemotherapy

Matthew Maurer Mayo Clinic, Rochester, MN, United States

Joseph Schroers-Martin

Detectable tumor-confirmed FL mutations in PB years prior to clinical diagnosis

Joseph Schroers-Martin Stanford University, Stanford, CA, United States

Frontline VEN+OBI and BEN in high tumor burden FL

Craig Portell University of Virginia, Charlottesville, VA, United States

Cell-of-origin risk stratification prior to immune profiling of DLBCL biopsies

Andrew Weng BC Cancer Agency, Vancouver, Canada

MCL R2 Elderly: R2 vs RTX maintenance after immunochemotherapy in MCL

Vincent Ribrag Gustave Roussy Institute, Villejuif, France

Session 1 panel discussion

Session 2: Novel Therapies

POLARIX: pola-R-CHP vs R-CHOP in previously untreated DLBCL

Hervé Tilly Henri Becquerel Center, Rouen, France

Elizabeth Budde

Mosunetuzumab monotherapy in patients with R/R FL with ≥2 prior LoT

Elizabeth Budde City of Hope, Duarte, CA, United States

Mark Roschewski

ACA prior to frontline therapy in untreated aggressive B-cell lymphoma

Mark Roschewski National Cancer Institute, Bethesda, MD, United States

Martin Hutchings

Glofitamab + polatuzumab vedotin in R/R DLBCL

Martin Hutchings Copenhagen University Hospital, Copenhagen , Denmark

Global Unity-NHL: umbralisib plus ublituximab in R/R MZL

Julio Chavez Moffitt Cancer Center, Tampa, FL, United States

CITADEL-203: parsaclisib in R/R FL

Ryan Lynch Seattle Cancer Care Alliance, Seattle, WA, United States

Session 2 panel discussion

Session 3: CLL & SLL

DFS results from MRD cohort of Captivate

Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy

Barbara Eichhorst

GAIA (CLL13): VEN-based time-limited combination treatments vs SOC in CLL

Barbara Eichhorst University Hospital Cologne, Cologne, Germany

NCRI FLAIR: IBR+RTX vs FCR in previously untreated CLL

Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

MAJIC: frontline ACA+VEN vs VEN+OBI in CLL or SLL

Matthew Davids Dana-Farber Cancer Institute, Boston, MA

Alessandra Tedeschi

SEQUOIA: frontline ZAN+VEN in CLL or SLL with del(17p)

Alessandra Tedeschi Niguarda Cancer Center, Milan, Italy

Constantine Tam

SEQUOIA: ZAN vs BEN+RTX in treatment-naïve CLL/SLL

Constantine Tam Peter MacCallum Cancer Centre, Victoria, Australia

Wojciech Jurczak

Ascend: ACA vs RTX+IDL or BEN in R/R CLL

Wojciech Jurczak Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland

Glow: MRD outcomes after fixed-duration IBR+VEN vs CLB+OBI in CLL

Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Session 3 panel discussion

Session 4: T-Cell Engagement & Therapies

Transform: liso-cel vs SOC + salvage chemotherapy and ASCT in R/R LBCL

Manali Kamdar University of Colorado Cancer Center, Denver, CO, United States

ZUMA-5: axi-cel in patients with R/R iNHL

Sattva Neelapu University of Texas MD Anderson Cancer Center, Houston, TX, United States

Catherine Thieblemont

Elara: tisa-cel in adult patients with high-risk R/R FL

Catherine Thieblemont Saint-Louis Hospital, Paris, France

First-in-human study of YTB323 CAR-T therapy in patients with R/R DLBCL

Ian Flinn Sarah Cannon Research Institute, Nashville, TN, United States

High durable remission rates after CD22-CAR-T therapy in adults with R/R LBCL

Matthew Frank Stanford University, Stanford, CA, United States

Real-world data from US Lymphoma CAR T Consortium: brexu-cel for R/R MCL

Yucai Wang Mayo Clinic, Rochester, MN, United States

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL

Natalie Grover UNC School of Medicine, Chapel Hill, NC, United States

Session 4 panel discussion

Meeting Supporters:

Visit The Lymphoma channel for the latest updates from leading experts